Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -14.03
- Piotroski Score 3.00
- Grade Neutral
- Symbol (SPPI)
- Company Spectrum Pharmaceuticals, Inc.
- Price $1.03
- Changes Percentage (-0.49%)
- Change -$0.01
- Day Low $0.97
- Day High $1.06
- Year High $1.57
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.
- Last Earnings 12/11/2012
- Ex-Dividend for 5/16 Dividend 12/18/2012
- Dividend Payable 12/28/2012
- Today N/A
- Next Earnings (Estimated) 11/07/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.75
- High Stock Price Target $0.75
- Low Stock Price Target $0.75
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.36
- Trailing P/E Ratio -2.8472222222222
- Forward P/E Ratio -2.8472222222222
- P/E Growth -2.8472222222222
- Net Income $-78,104,000
